

Yajing Xing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8449417/publications.pdf>

Version: 2024-02-01

8
papers

210
citations

1478505
6
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

381
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of <i>N</i> -Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 676-695.	6.4	22
2	A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 422.	8.6	23
3	Synthesis and biological evaluation of methylpyrimidine-fused tricyclic diterpene analogs as novel oral anti-late-onset hypogonadism agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 176, 21-40.	5.5	4
4	Synthesis and biological evaluation of 3-nitro-4-chromanone derivatives as potential antiproliferative agents for castration-resistant prostate cancer. <i>RSC Advances</i> , 2019, 9, 33794-33799.	3.6	4
5	Synthesis of Cyanoenone-Modified Diterpenoid Analogs as Novel Bmi-1-Mediated Antitumor Agents. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1105-1110.	2.8	11
6	Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway. <i>Science China Life Sciences</i> , 2017, 60, 417-428.	4.9	59
7	The synthesis and antitumor activity of lithocholic acid and its derivatives. <i>Steroids</i> , 2017, 125, 54-60.	1.8	21
8	Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer. <i>Oncotarget</i> , 2015, 6, 15348-15361.	1.8	66